Manhattan Pharmaceuticals to Present at ValueRich Small-Cap Financial Expo
Sep 14, 2005
NEW YORK, NY SEPT. 14 - Manhattan Pharmaceuticals, Inc.' (MHTT.OB) president and chief executive officer, Douglas Abel, will present an overview of the company and its obesity drug Oleoyl-estrone at the ValueRich Small-cap Financial Expo at The Javits Center, New York, Thursday September 15.
Mr. Abel' presentation will start at 2:00pm EDT.
Mr. Abel will cover early results of a Phase Ia human safety trial of the company' obesity drug candidate which were originally announced last week at the Oppenheimer & Co. Diabetes Conference in New York.
About Manhattan Pharmaceuticals, Inc.
Manhattan Pharmaceuticals, Inc. (http://www.manhattanpharma.com/), a development stage pharmaceutical company, acquires and develops proprietary prescription drugs for large, underserved patient populations. In view of the worldwide obesity epidemic, the Company is developing Oleoyl estrone, an orally administered novel therapeutic for weight loss. To meet the needs of other major, underserved medical markets while lowering development risks, Manhattan Pharmaceuticals also combines FDA-approved drugs with novel delivery technologies and formulations. The Company is developing a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures.